The company offers an AI‑enhanced therapeutic discovery platform that combines multi‑omics target identification, high‑throughput phenotypic screening, and rapid in vivo validation with GMP‑grade compound synthesis. It provides cloud‑based data integration, analytics, and regulatory support to help biotech and pharmaceutical partners accelerate early‑stage drug development while lowering R&D costs.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease areas lack effective therapies because existing drug pipelines rely on legacy target discovery methods that are slow, costly, and often fail to translate preclinical findings into clinical success. This creates a gap between patient needs and available treatment options, especially for rare and complex disorders.
Solution
The company operates a fully integrated therapeutic development platform that accelerates early‑stage drug discovery through AI‑driven target identification, high‑throughput phenotypic screening, and rapid in vivo validation. By combining proprietary bioinformatics pipelines with scalable cell‑based assays, it shortens the hit‑to‑lead cycle and improves predictive confidence. The platform also offers GMP‑grade compound synthesis and regulatory‑ready documentation to streamline IND filing. Clients can access a secure cloud portal that aggregates assay data, model predictions, and project milestones, enabling real‑time decision making. This end‑to‑end approach reduces R&D spend and de‑riskes the transition from preclinical research to clinical development.
Target Audience
Primary customers are mid‑size biotech firms and large pharmaceutical R&D divisions seeking to outsource early‑stage discovery, as well as academic research groups looking for a commercial pathway to translate their findings into therapeutic candidates.
Features
- AI‑enhanced target discovery engine that integrates genomics, proteomics, and disease‑specific phenotypic data
- Automated high‑throughput screening (HTS) of >1 million compounds per week with robotic liquid handling and real‑time quality control
- In vivo efficacy and pharmacokinetic modeling using CRISPR‑engineered mouse and zebrafish disease models
- GMP‑compliant synthesis and formulation services with on‑demand scale‑up capability
- Cloud‑based data lake and analytics dashboard with API access for seamless integration into client LIMS
- Regulatory support package including pre‑IND briefing documents, safety pharmacology packages, and CMC strategy outlines
- Intellectual property management tools that track novelty, freedom‑to‑operate, and patent filing timelines